Axsome Therapeutics, Inc (AXSM) Financials
Key financial figures for Axsome Therapeutics, Inc (Q2 2026).
Axsome grew total net product revenue 46% year-over-year to $218.4 million in Q2 2026, led by AUVELITY's launch into Alzheimer's disease agitation and continued MDD prescription growth. Total net product revenue was $218.4 million (+46% YoY), roughly in line with the sequential ramp seen over the past several quarters. AUVELITY net product sales reached $180.3 million (+51% YoY); AUVELITY launched for Alzheimer's disease agitation in June 2026, and new-to-brand prescriptions among patients 65+ rose 126% in the first eight weeks of that launch versus the prior quarter. Figures are for Q2 2026, as Axsome Therapeutics Inc. reported them.
- Revenue
- $218M
- Net Income
- -$51M
- EPS
- $-0.99
- Total Assets
- $761M
- Operating Cash Flow
- -$33M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $218M | -$51M | -$0.99 | -22.73% | |
| Q1 FY2026 | $191M | -$65M | -$1.26 | -33.14% | -$21M |
| Q4 FY2025 | $196M | -$29M | -$0.56 | -15.02% | -$19M |
| Q3 FY2025 | $171M | -$47M | -$0.94 | -26.97% | $988K |
| Q2 FY2025 | $150M | -$48M | -$0.97 | -24.47% | -$32M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $638M | -$183M | -$3.68 | -26.51% | -$94M |
| FY2024 | $386M | -$287M | -$5.99 | -72.74% | -$129M |
| FY2023 | $271M | -$239M | -$5.27 | -85.67% | -$146M |
Frequently asked questions
What was Axsome Therapeutics Inc.'s revenue last quarter?
Axsome Therapeutics Inc. reported revenue of $218.4 million for Q2 FY2026, up 45.5% from the same period a year earlier.
Is Axsome Therapeutics Inc. profitable?
Not in its most recent reported period. Axsome Therapeutics Inc. reported a net loss of $51.3 million for Q2 FY2026, a net margin of -23.5% on revenue.
How has Axsome Therapeutics Inc.'s margin trended?
Operating margin was -22.73% in Q2 FY2026, compared with -24.47% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How many quarters of Axsome Therapeutics Inc. financials does SentiSense hold?
SentiSense holds up to forty quarters and twenty fiscal years of income statement, balance sheet and cash flow history for AXSM. The 5 most recent quarters are summarised above.
Full income statement, balance sheet and cash flow for Axsome Therapeutics, Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.